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Abstract
Diffuse leptomeningeal glioneuronal tumors (DLGNT) represent rare CNS neoplasms which have been included in the 2016 
update of the WHO classification. The wide spectrum of histopathological and radiological features can make this enigmatic 
tumor entity difficult to diagnose. In recent years, large-scale genomic and epigenomic analyses have afforded insight into 
key genetic alterations occurring in multiple types of brain tumors and provide unbiased, complementary tools to improve 
diagnostic accuracy. Through genome-wide DNA methylation screening of > 25,000 tumors, we discovered a molecularly 
distinct class comprising 30 tumors, mostly diagnosed histologically as DLGNTs. Copy-number profiles derived from the 
methylation arrays revealed unifying characteristics, including loss of chromosomal arm 1p in all cases. Furthermore, this 
molecular DLGNT class can be subdivided into two subgroups [DLGNT methylation class (MC)-1 and DLGNT methyla-
tion class (MC)-2], with all DLGNT-MC-2 additionally displaying a gain of chromosomal arm 1q. Co-deletion of 1p/19q, 
commonly seen in IDH-mutant oligodendroglioma, was frequently observed in DLGNT, especially in DLGNT-MC-1 cases. 
Both subgroups also had recurrent genetic alterations leading to an aberrant MAPK/ERK pathway, with KIAA1549:BRAF 
fusion being the most frequent event. Other alterations included fusions of NTRK1/2/3 and TRIM33:RAF1, adding up to an 
MAPK/ERK pathway activation identified in 80% of cases. In the DLGNT-MC-1 group, age at diagnosis was significantly 
lower (median 5 vs 14 years, p < 0.01) and clinical course less aggressive (5-year OS 100, vs 43% in DLGNT-MC-2). Our 
study proposes an additional molecular layer to the current histopathological classification of DLGNT, of particular use for 
cases without typical morphological or radiological characteristics, such as diffuse growth and radiologic leptomeningeal 
dissemination. Recurrent 1p deletion and MAPK/ERK pathway activation represent diagnostic biomarkers and therapeutic 
targets, respectively—laying the foundation for future clinical trials with, e.g., MEK inhibitors that may improve the clinical 
outcome of patients with DLGNT.
Keywords Diffuse leptomeningeal glioneuronal tumor · Pediatric · Brain tumor · Methylation · Prognostic · Subgroup
Introduction
Diffuse leptomeningeal glioneuronal tumors (DLGNTs) 
represent rare CNS neoplasms, preferentially occurring in 
children but with several cases in adult patients having also 
been reported [9, 10, 26, 31]. A gender predilection is appar-
ent, with males being more commonly affected. Among 81 
patients in 20 different reports, 62% (50/81) were male [1, 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-018-1865-4) contains 
supplementary material, which is available to authorized users.
 * Felix Sahm 
 felix.sahm@med.uni-heidelberg.de
 * David T. W. Jones 
 david.jones@kitz-heidelberg.de
Extended author information available on the last page of the article
240 Acta Neuropathologica (2018) 136:239–253
1 3
3, 6, 8–10, 12, 13, 15, 16, 19, 25, 27, 29–31, 33, 35–37]. 
A summary of characteristics in previous series is given 
in Table 1. Although most tumors display a slow progres-
sion, aggressive cases were occasionally encountered [12, 
29, 31, 36]. The largest series with follow-up data of 24 
patients showed 9 deaths within 3–21 years [31]. Treatment 
regimens, where given, typically included surgical resection, 
radiotherapy and/or chemotherapy.
In previous reports, the majority of DLGNTs were radio-
logically characterized by leptomeningeal enhancement on 
MRI in the posterior fossa, around the brain stem and along 
the spinal cord. Small cystic or nodular T2-hyperintense 
lesions were frequently encountered along the subpial sur-
face of the brain and spinal cord. Discrete intraparenchymal 
lesions were also found, especially in the spinal cord [1, 12, 
15, 29, 31, 35]. However, in a recent study by Chiang et al. 
comprising five patients, leptomeningeal dissemination was 
not seen radiologically in any of the cases, suggesting that 
DLGNTs do not necessarily present with gross leptomenin-
geal dissemination on MRI [9].
Histologically, DLGNTs have been described as low- to 
moderate-cellularity lesions consisting of relatively mono-
morphous oligodendrocyte-like cells with round to oval 
nuclei, inconspicuous nucleoli and a ‘glioneural commit-
ment’ [15], embedded in a desmoplastic or myxoid leptome-
ningeal stroma [29, 31]. While a low mitotic activity was 
most commonly observed, features of anaplasia were also 
seen in a number of cases [31, 36]. Immunohistochemical 
features of the tumor cells appear to include strong reactiv-
ity for OLIG2, MAP2 and S100, with variable expression 
for GFAP and synaptophysin. Immunostaining for NeuN, 
EMA and mutant IDH1 (R132H) was negative [9, 29, 31, 
35]. Although typically displaying a low Ki-67 prolifera-
tion index, several cases with elevated proliferation were 
reported [29, 31, 35, 36], with less favorable outcome asso-
ciated with an index > 4% [31, 36]. The wide spectrum of 
histological and radiological features encountered, as well 
as its rarity and relatively recent inclusion in the WHO clas-
sification, can make this tumor entity difficult to diagnose.
In recent years, large-scale genomic and epigenomic 
analyses have provided insight into key genetic alterations 
occurring in multiple types of brain tumors. For example, 
various mechanisms converging on an aberrant activation 
of the mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) signaling pathway [20, 21, 
39, 43] represent a hallmark of pediatric low-grade gliomas, 
with KIAA1549:BRAF fusion being the most frequent event 
[23, 24, 28]. Alternative mechanisms such as NTRK and 
RAF1 rearrangements, also converging on activation of the 
MAPK/ERK pathway, were also discovered [2, 23, 24, 43].
The existence of KIAA1549:BRAF fusions in DLGNT has 
also been described in recent publications, in conjunction 
with deletion of chromosomal arm 1p or 1p/19q co-deletion 
but in the absence of IDH mutation (Table 1) [1, 9, 12, 30, 
32, 33, 35].
Herein, we performed a DNA methylation, copy number 
and targeted sequencing-based molecular characterization of 
this entity to clarify the underlying molecular and biological 
mechanisms and to detect potentially targetable alterations. 
In addition, molecular features were correlated with clini-
cal, neuropathological and radiological findings, leading to 
the delineation of two molecularly and clinically distinct 
subsets of DLGNT.
Materials and methods
Tumor material and patient population
Tumor samples and clinical data were provided by multi-
ple international collaborating centers and collected at the 
German Cancer Research Center (DKFZ, Heidelberg, Ger-
many) with approval from the respective institutional review 
boards. Informed consent was obtained from all patients 
according to the local protocols. Clinical patient details are 
listed in Supplementary table 1.
DNA methylation profiling
The Illumina Infinium HumanMethylation450 (450k) array 
and Illumina Infinium MethylationEPIC (EPIC) array were 
used to obtain genome-wide DNA methylation profiles, 
according to the manufacturer’s instructions (Illumina, San 
Diego, USA). Data were generated at the Genomics and Pro-
teomics Core Facility of the DKFZ (Heidelberg, Germany) 
and St. Jude Children’s Research Hospital (Memphis, USA). 
DNA methylation data was generated from both fresh-frozen 
and formalin-fixed paraffin-embedded (FFPE) tissue sam-
ples. On-chip quality metrics of all samples were carefully 
controlled.
Copy-number variation (CNV) analysis from 450k and 
EPIC methylation array data was performed using the conu-
mee Bioconductor package version 1.12.0.
All computational analyses were performed in R ver-
sion 3.4.1 (R Development Core Team, 2018). Raw signal 
intensities were obtained from IDAT-files using the minfi 
Bioconductor package version 1.24.0 [4]. Illumina EPIC and 
450k samples were merged to a combined data set by select-
ing the intersection of probes present on both arrays (com-
bineArrays function, minfi). Each sample was individually 
normalized by performing a background correction (shift-
ing of the 5th percentile of negative control probe intensi-
ties to 0) and a dye-bias correction (scaling of the mean of 
normalization control probe intensities to 10,000) for both 
color channels. Subsequently, a correction for the type of 
material tissue (FFPE/frozen) and array (450k/EPIC) was 
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performed by fitting univariate, linear models to the log2-
transformed intensity values (removeBatchEffect function, 
limma package version 3.34.5). The methylated and unmeth-
ylated signals were corrected individually. Beta-values were 
calculated from the retransformed intensities using an offset 
of 100 (as recommended by Illumina).
Before further analysis, the following filtering criteria 
were applied: Removal of probes targeting the X and Y 
chromosomes (n = 11,551), removal of probes containing 
a single-nucleotide polymorphism (dbSNP132 Common) 
within five base pairs of and including the targeted CpG-site 
(n = 7998), probes not mapping uniquely to the human refer-
ence genome (hg19) allowing for one mismatch (n = 3965), 
and 450k array probes not included on the EPIC array. In 
total, 428,230 probes were kept for downstream analysis.
To perform unsupervised dimension reduction, the 
remaining probes were used to calculate the 1-variance 
weighted Pearson correlation between the samples. The 
resulting distance matrix was used as input for t-SNE anal-
ysis (t-Distributed Stochastic Neighbor Embedding; Rtsne 
package version 0.13) [41]. The following non-default 
parameters were applied: theta = 0, pca = F, max_iter = 2500 
perplexity = 20.
To perform unsupervised hierarchical clustering, the 
10,000 probes with highest standard deviation were selected 
to calculate the Euclidean distance between samples, fol-
lowed by applying Wards linkage method for sample cluster-
ing. In the heatmap, representation probes were reordered 
by complete linkage hierarchical clustering of the Euclidean 
distance between probes.
To evaluate focal amplifications and deletions and chro-
mosomal gains and losses, we visually inspected copy-num-
ber profiles of each case. Candidate genes and their 3′ and 
5′ intergenic neighborhood were further investigated using 
the Integrative Genomic Viewer (IGV) [40] for the presence 
of breakpoints, as an indication for potential gene fusions.
Histopathology
Where possible, hematoxylin and eosin (H&E) stained for-
malin-fixed paraffin-embedded (FFPE) sections from tumors 
in the DLGNT methylation class (n = 14/30) were reviewed 
by an experienced neuropathologist (FS or DWE) according 
to WHO 2016 guidelines.
Gene panel sequencing/single gene testing
For the detection of single-nucleotide variations, small 
insertions and deletions (indels), fusions, and copy number 
aberrations, a subset of samples (n = 5) was subjected to cus-
tomized enrichment/hybrid-capture-based next-generation 
sequencing gene panel analysis covering 130 genes of par-
ticular relevance in brain tumors, as previously described 
[34]. The presence of KIAA1549-BRAF fusion transcripts 
was tested in four samples by reverse transcription polymer-
ase chain reaction (RT-PCR). Additionally, single gene test-
ing was performed via immunostaining for BRAF p.V600E 
(VE1; Ventana Medical Systems, Inc., Tucson, USA; 
ready-to-use), histone H3 p.K27M (EMD; Merck Millipore, 
Darmstadt, Germany 1:600) and IDH1 p.R132H (Dianova, 
Hamburg, Germany; 1:600) mutant proteins in five cases 
(Supplementary data).
Statistics
Overall survival (OS) and progression-free survival (PFS) 
were evaluated by Kaplan–Meier analysis and log-rank test. 
Binary and categorical patient characteristics between sub-
groups were compared via two-sided Fisher’s exact test. p 
values < 0.05 were considered significant.
Results
DNA methylation profiling defines molecular DLGNT 
classes
Recent large-scale genomic and epigenomic studies dem-
onstrated that the DNA methylation pattern of tumor cells 
can provide valuable information for tumor classification. 
These DNA methylation patterns are thought to represent 
a preserved ‘molecular memory’ of the respective cell of 
origin throughout the course of disease, thus displaying a 
distinct signature for each biologically discrete tumor entity 
[7, 17, 18, 38].
Through genome-wide DNA methylation screening 
of > 25,000 tumors in the extended Heidelberg cohort, an 
apparently distinct class comprising 30 tumors was detected, 
of which the most were diagnosed histologically as DLGNT. 
A subsequent focused unsupervised analysis of DNA meth-
ylation patterns of these tumors together with 129 well-
characterized reference samples representing CNS tumors 
of known histological and/or molecular subtype confirmed 
the distinct nature of this class (Fig. 1).
Furthermore, this molecular DLGNT group could be 
divided into two subclasses (Fig. 1b) through DNA methyla-
tion clustering; thus, we subsequently refer to these groups 
as DLGNT methylation class (MC)-1 (n = 17) and DLGNT-
MC-2 (n = 13).
Initial diagnoses of DLGNT
Initial diagnoses were available for 17/17 DLGNT-MC-1 
and 13/13 DLGNT-MC-2 tumors. ‘Diffuse leptomeningeal 
glioneuronal tumor’ represented the most frequent initial 
diagnosis in both subgroups (DLGNT-MC-1: 8/17, 47%; 
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DLGNT-MC-2: 5/13, 38%). Various other tumors were 
diagnosed as primitive neuroectodermal tumors WHO IV 
(DLGNT-MC-1: 4/15, 27%; DLGNT-MC-2: 2/13, 15%), 
pilocytic astrocytoma WHO I (2/17, 12% in DLGNT-
MC-1; 2/13, 15% in DLGNT-MC-2) or anaplastic astrocy-
toma WHO III (1/17, 6% in DLGNT-MC-1; 2/13, 15% in 
DLGNT-MC-2) as well as single cases as extraventricular 
and atypical neurocytoma WHO grade II, oligodendro-
glioma WHO III and ganglioglioma WHO grade I. Thus, 
the biologically defined DLGNT class appears to be associ-
ated with a substantial morphological heterogeneity, lead-
ing to a substantial risk of misdiagnosis when relying on 
histology alone. To examine this further, as many cases as 
possible were re-evaluated by experienced neuropathologists 
(FS, DWE).
HE-stained FFPE sections were available for 9 DLGNT-
MC-1 and 5 DLGNT-MC-2 tumors (see Fig. 2 for exam-
ples). Histologically, they presented as moderate- to high-
cellularity neoplasms with low mitotic activity. Tumor cells 
most commonly displayed isomorphic, round to oval nuclei 
(11/14, 79%) with inconspicuous nucleoli, with some other 
tumors (4/14, 29%) displaying small eccentric nuclei.
Oligodendroglioma-like perinuclear haloes were more 
frequently observed in the DLGNT-MC-1 subgroup (8/9, 
89% vs 2/5, 40% in DLGNT-MC-2). The tumors displayed 
desmoplastic and myxoid areas, sometimes with fibrillary 
components. In both subgroups, microcysts and neuropil-
like islands were observed. In addition, DLGNT-MC-1 
and DLGNT-MC-2 occasionally harbored eosinophilic 
granular bodies and Rosenthal fibers together with vas-
cular proliferation. Hyalinization of the vascular walls 
was encountered in the periphery of the biopsies in 
two DLGNT-MC-1 cases. Microscopic leptomeningeal 
involvement was detected in 6 cases, in which 5 cases 
were inconspicuous at radiological presentation. The pres-
ence of gemistocytes was demonstrated in one DLGNT-
MC-2 biopsy. Signs of necrosis were absent in all tumor 
specimens.
In our series, 9/17 DLGNT-MC-1 and 8/13 DLGNT-
MC-2 patients were initially not diagnosed with DLGNT. 
Thereof, 16/17 patients were diagnosed before the release 
of the WHO classification from 2016, in which the tumor 
entity of DLGNT was officially introduced, potentially 
explaining some of the discrepancy. Due to the wide 
spectrum of histological features described in the WHO 
classification from 2016, all cases assessed here would 
be histologically compatible with DLGNT, although other 
diagnoses would still have been favored based on histology 
alone in some cases [26].
Fig. 1  Molecular classification of DLGNTs by DNA methylation 
profiling. Unsupervised hierarchical clustering analysis (a) of 30 
DLGNT samples was performed based on the 10,000 most variably 
methylated probes. The existence of distinct DLGNT methylation 
classes (DLGNT-MC-1, DLGNT-MC-2) was demonstrated through 
unsupervised hierarchical clustering and t-SNE analysis (b). DLGNT-
MC-1 and DLGNT-MC-2 samples were compared with 129 well-
characterized reference samples representing CNS tumors of known 
histological and/or molecular subtype, confirming the distinct nature 
of both DLGNT methylation classes. AAP anaplastic astrocytoma 
with piloid features, EVN extraventricular neurocytoma, HGG_MID 
midline high-grade glioma, DNET dysembryoplastic neuroepithelial 
tumor, GG ganglioglioma, PA_MID midline pilocytic astrocytoma, 
RGNT rosette-forming glioneuronal tumor, O_IDH 1p19q-codeleted 
IDH-mutant glioma, PA_CORT hemispheric PA, PA_INF infratento-
rial PA
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Varying radiological features of DLGNTs
Comprehensive radiological data were available for 10 
DLGNT-MC-1 and 5 DLGNT-MC-2 patients (examples 
are given in Fig. 3). Evaluation of available MRI series 
revealed T2 hyperintense cystic lesions or nodular masses 
both along the surface and also within the parenchyma of 
the spinal cord (14/15, 93%) with occasional involvement 
of the cerebellum (5/15, 33%). The overall proportion of 
cases reported as spinal, however, was lower (11/13, 85% in 
DLGNT-MC-1, 7/12, 58% in DLGNT-MC-2) than that for 
those cases with MRI data available. Hereby, we excluded 
three cases due to their preselection based on their exclu-
sive spinal involvement, previously reported in Chiang et al. 
[9]. During the process of tumor progression, supratentorial 
regions including the cerebral cortex, basal ganglia and thal-
amus were additionally affected in a subset cases. Only one 
DLGNT-MC-1 patient displayed intraparenchymal lesions 
exclusively in the left frontal lobe of the cerebral cortex 
without spinal involvement. Some of the cystic or nodu-
lar lesions showed contrast agent uptake, while others did 
not, suggesting a generally mixed presentation with variable 
enhancement.
Previous studies reported that one of the key features 
of DLGNTs is its diffuse leptomeningeal enhancement 
on MRI. In our series, contrast enhancement of the lep-
tomeninges was more frequently observed in DLGNT-
MC-2 (4/5 vs 3/10 in DLGNT-MC-1; p = 0.12), where 
it particularly involved the surface of the cerebellum, 
basal cisterns and the spinal cord. The surface of these 
Fig. 2  Histopathological features of molecularly defined DLGNT. 
a Case DLGNT-MC-1_09: The DLGNT-MC-1 samples frequently 
display cells with round, central nuclei and oligodendroglioma-
like perinuclear haloes, encompassed by desmoplastic stroma. b 
Case DLGNT-MC-2_10: Tumor cells of the DLGNT-MC-2 entity 
exhibit small, round nuclei without oligodendroglioma-like perinu-
clear haloes. Myxoid changes were present in two cases. c, d Case 
DLGNT-MC-1_13: Tumor cells with oligodendroglioma-like peri-
nuclear haloes surrounded by neuropil-like islands were occasion-
ally observed in the DLGNT-MC-1 subgroup. Vascular proliferation 
was regularly encountered in both subgroups. Mitosis visible (arrow). 
e, f Case DLGNT-MC-1_05: Tumor samples from both subgroups 
occasionally demonstrated microcysts and hyalinized vessels (e). 
Rosenthal fibers (f) were frequently encountered, especially in the 
DLGNT-MC-1 subgroup. Scale bars represent 300 µm
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regions appeared to be covered by a thin ‘sugar coat’, in 
some cases extending from the brain stem down to the 
conus medullaris, and spanning multiple segments. In a 
few cases, spinal nerve roots appeared to be thickened. 
Leptomeningeal dissemination throughout the central 
nervous system was observed in several patients with 
disease progression. Importantly, however, a consider-
able subset of DLGNTs as defined here did not present 
with leptomeningeal enhancement or dissemination radio-
logically (7/10 in DLGNT-MC-1, 1/5 in DLGNT-MC-2), 
supporting the notion that leptomeningeal enhancement 
on MRI should not be viewed as an essential criterion for 
diagnosing DLGNT [9]. Interestingly, one case for which 
longitudinal imaging data were available indicated a pro-
gression from a circumscribed mass at initial presentation 
to a disseminated lesion at later follow-up (over a period 
of roughly 5 years).
DLGNT‑MC‑1 and DLGNT‑MC‑2 show distinct 
copy‑number profiles
Copy-number profiles derived from DNA methylation 
arrays revealed some unifying characteristics of biologi-
cally defined DLGNT, including loss of chromosomal arm 
1p in 100% of cases. All DLGNT-MC-2, but only 6/17 
(35%) of DLGNT-MC-1 showed an additional gain of 
chromosomal arm 1q (p < 0.001) (see Fig. 4). Co-deletions 
of 1p/19q were frequently encountered in the DLGNT-
MC-1 group (8/17, 47% vs 2/13, 15% in DLGNT-MC-2; 
p = 0.12). In contrast, gain of chromosome 8 was more 
commonly observed in DLGNT-MC-2 (7/13, 54% vs 
1/17, 6% in DLGNT-MC-1; p < 0.01). Homozygous dele-
tion of CDKN2A/B was found in one DLGNT-MC-2 with 
KIAA1549:BRAF fusion.
Fig. 3  Radiological features of 3 representative cases of DLGNTs. 
[DLGNT-MC-1_10 (a–c), DLGNT-MC-2_09 (d–e), DLGNT-
MC-2_03 (f)]. Axial and sagittal, T2-weighted MRI images (a–g) 
reveal T2 hyperintense, multicystic lesions with nodular enhancement 
in the cerebellum (a, b, d) and cervical spinal cord spanning several 
segments (b, c, f) with ‘sugar-coating like’ leptomeningeal enhance-
ment covering the cerebellum (d, e)
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Genetic rearrangements leading to aberrant MAPK/
ERK pathway
In addition to larger scale chromosomal alterations, most 
cases also displayed gain of 7q34 indicative of tandem dupli-
cation leading to KIAA1549:BRAF fusion (11/17, 65% in 
DLGNT-MC-1 vs 9/13, 69% in DLGNT-MC-2). In both 
subgroups, this represented the most recurrent genetic altera-
tion after 1p loss. BRAF fusions leading to constitutive acti-
vation of the MAPK/ERK pathway, is a well-known driving 
oncogenic event in other (particularly pediatric) low-grade 
gliomas [20–23].
Multiple additional fusions resulting in an aberrant 
MAPK/ERK pathway were indicated by copy number altera-
tions in DLGNT-MC-1 cases, including fusions involving 
NTRK1/2/3 present in one case each with currently undeter-
mined fusion partners. In one DLGNT-MC-2 case, for which 
RNA sequencing data were available, a TRIM33:RAF1 
fusion was discovered. RAF1 is a human homolog of the 
v-raf gene from a transforming retrovirus and involved in 
cell proliferation, survival, migration and a range of other 
cellular processes [5, 42]. RAF1 fusions have been reported 
to possess constitutive kinase activity and transforming 
ability, underlining their role in tumorigenesis, especially 
in pilocytic astrocytoma [11, 14, 24]. All MAPK pathway 
alterations mentioned above were mutually exclusive.
Targeted sequencing/next‑generation (NGS) gene 
panel sequencing
Using next-generation (NGS) gene panel sequencing and 
reverse transcription polymerase chain reaction (RT-PCR), 
we additionally analyzed ten samples, including seven 
DLGNT-MC-1 and three DLGNT-MC-2 cases. The pres-
ence of a KIAA1549-BRAF fusion had already been detected 
in the copy-number profiles of these samples. Immunostain-
ings for BRAF p.V600E, histone H3 p.K27M and IDH1 
p.R132H mutant proteins were available for additionally 
one DLGNT-MC-1 and one DLGNT-MC-2 cases. Evalu-
able data in seven cases confirmed KIAA1549-BRAF fusions 
with KIAA1549 exon 15 fusing to BRAF exon 11 in two 
DLGNT-MC-1 cases and to BRAF exon 9 in three DLGNT-
MC-1 and one DLGNT-MC-2 cases. Fusion of KIAA1549 
exon 13 to BRAF exon 11 was demonstrated in one DLGNT-
MC-2 sample.
None of the cases displayed alterations in IDH1 R132 
(0/10), IDH2 R172 (0/5), BRAF V600E (0/7), H3F3A G34 
(0/5) and H3F3A K27 (0/8). Point mutations in the pro-
moter region of TERT (C228T and C228A) were encoun-
tered in 2/6 DLGNT-MC-2 patients, but not in any of the 9 
DLGNT-MC-1 cases tested. One tumor sample exhibited a 
point mutation in ATRX and a frameshift insertion in BCOR; 
however, the functional relevance of these alterations in this 
context remains unknown.
Clinical characteristics and outcome
We correlated the genetic and methylation data of both 
subgroups with available basic clinical parameters. Age at 
diagnosis was significantly lower in DLGNT-MC-1 patients 
(median 5 vs 14 years in DLGNT-MC-2; p < 0.01). Only one 
patient whose tumor was classified as ‘DLGNT-MC-1’ was 
older than 18, whereas DLGNT-MC-2 showed a clear predi-
lection for older age at diagnosis (range 5–47 vs 2–23 years 
in DLGNT-MC-1). Table 2 shows a summary of clinical and 
molecular parameters for the two subgroups.
Both methylation subgroups displayed a male pre-
dominance (M:F 1.4:1 in DLGNT-MC-1, 1.6:1 in 
DLGNT-MC-2).
Diffuse leptomeningeal glioneuronal tumors were located 
throughout the central nervous system, but preferentially in 
the spinal cord in both subgroups (11/13, 85% in DLGNT-
MC-1 and 7/12, 58% in DLGNT-MC-2), often spanning 
across multiple segments. Most patients exhibited multiple 
tumor sites at presentation (Fig. 5), making it challenging 
to assess the most common site of the primary lesion. No 
association between tumor location and a specific molecular 
alteration was identified.
In DLGNT-MC-1 patients with available follow-up data 
(n = 9), disease progression was observed in two cases (2/9). 
All DLGNT-MC-1 patients were alive at the time of latest 
follow-up. Outcome data of DLGNT-MC-2 patients (n = 8) 
presented a significantly more aggressive clinical course 
with 7/8 patients displaying disease progression. In addition, 
four DLGNT-MC-2 patients (4/8) eventually died after 10, 
50, 52 and 173 months from initial diagnosis. Two further 
DLGNT-MC-2 patients were transferred into palliative care 
after 17 and 132 months due to dismal physical condition, 
and were thereafter lost to follow-up. Although based on 
relatively small numbers, we believe that DLGNT-MC-2 
tumors present with a significantly more aggressive clinical 
course (5-year OS 43 vs 100% in DLGNT-MC-1, p < 0.05) 
(Fig. 6).
Due to the variable initial histological and imaging 
features of the tumors of these two distinct methylation 
classes, a wide spectrum of treatment regimens was applied, 
Fig. 4  Representative copy-number profiles of DLGNT-MC-1 (a) 
and DLGNT-MC-2 (b). Copy-number profiles derived from DNA 
methylation arrays revealed loss of chromosomal arm 1p in 100% 
of cases. All tumor samples in DLGNT-MC-2 (b) exhibit character-
istic gain of chromosomal arm 1q (vs 35% in DLGNT-MC-1), with 
several also showing gain of whole chromosome 8 (7/13, 54% vs 
1/17, 6% in DLGNT-MC-1). Tumor samples from both subgroups 
frequently demonstrate a tandem duplication at 7q34 indicating 
KIAA1549:BRAF fusion (c)
◂
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including surgical resection, chemotherapy and radiotherapy. 
Thus, no conclusions can currently be drawn as to the effi-
cacy of particular therapeutic regimes.
Discussion
In the past, various terms were attributed to DLGNTs, such 
as ‘disseminated oligodendroglial-like leptomeningeal tumor 
of childhood’ [31], ‘superficially disseminated glioma in 
children’ [1], ‘primary disseminated leptomeningeal oligo-
dendroglioma’ [6] or ‘diffuse leptomeningeal neuroepithelial 
tumor’ [35], emphasizing the leptomeningeal involvement. 
However, a recent report comprising five cases by Chiang 
et al. characterized DLGNTs as low-grade spinal glioneu-
ronal tumors without conspicuous radiological features at 
presentation. Leptomeningeal dissemination on MRI was not 
visible in a considerable proportion of molecularly defined 
DLGNTs in our series and, thus, should not be applied as 
mandatory criterion for diagnosis. A characteristic appear-
ance of multicystic or nodular, T2 hyperintense lesions in 
the cerebellum and spinal cord (as part of the multi-focal 
presentation) was observed in all 30 cases.
Microscopic leptomeningeal lesions were detected during 
neuropathological review in 6/14 (43%) tumors, whereby 
MRI was inconspicuous in five cases. However, morphologi-
cal classification of DLGNT appeared to be difficult based 
on histopathology and imaging only. Although DLGNT rep-
resented the most common initial diagnosis in this molecu-
larly defined series, a considerable subset of tumors were 
initially designated to other tumor entities including primi-
tive neuroectodermal tumors WHO grade IV, pilocytic astro-
cytoma WHO grade I, anaplastic astrocytoma WHO grade 
III, anaplastic oligodendrogioma WHO grade III, extraven-
tricular neurocytoma WHO grade II or ganglioglioma WHO 
grade I. In particular, the high prevalence of morphological 
‘oligodendroglial’ elements in DLGNT may suggest that 
some tumors currently diagnosed as ‘pediatric-type’ oligo-
dendroglioma could belong to the DLGNT molecular group.
A number of the characteristic features of DLGNT as 
described here, however, are not represented in the differ-
ential diagnostic entities mentioned above. Co-deletions of 
1p/19q are absent in pilocytic astrocytoma but are observed 
in adult oligodendroglioma. In contrast to adult oligodendro-
glioma, however, IDH mutations were absent in DLGNTs, 
while the KIAA1549:BRAF fusion, usually associated with 
pilocytic astrocytoma, was common. The cell of origin for 
this molecular tumor class remains unclear, but the mix-
ture of partially oligodendroglial-like and partially PA-like 
molecular features could tentatively suggest a precursor 
population just upstream of this lineage segregation.
Our study identified two molecular DLGNT subgroups 
(DLGNT-MC-1 and DLGNT-MC-2) with distinct molecular Ta
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and clinical features. Characteristics common to both classes 
of DLGNT include loss of chromosomal arm 1p. This is 
variably associated with 19q co-deletion, in keeping with 
previous reports [1, 9, 12, 30, 32, 33, 35]. Furthermore, all 
tumors in the DLGNT-MC-2 subgroup additionally display 
gain of chromosomal arm 1q, which was not reported to 
date.
Recurrent genetic alterations converging on an aberrant 
activation of the MAPK/ERK pathway were also high-
lighted in our series, with KIAA1549:BRAF fusion being 
the most frequent event (20/30 cases, 66%), in keeping 
with previous studies [9, 12, 32]. Other alterations includ-
ing fusions of NTRK1/2/3 and TRIM33:RAF1 were also 
detected. Both NTRK and RAF1 rearrangements result in 
a constitutive activation of the MAPK/ERK pathway and 
are known to facilitate tumorigenesis [2, 23, 24, 43]. Thus, 
we conclude that an aberrant activation of the MAPK/ERK 
pathway together with loss of 1p are hallmark alterations 
of the molecularly defined DLGNT entity. However, loss 
of 1p does not represent an exclusive marker and can be 
seen in other entities, hence, highlighting the essential role 
of methylation classification in diagnosing DLGNT-MC-1 
or MC-2.
Notably, age at diagnosis was significantly lower (median 5 
vs 14 years, p < 0.01) and clinical outcome less aggressive in 
DLGNT-MC-1 patients (5-year OS 100 vs 43% in DLGNT-
MC-2, p < 0.05). Based on our survival analysis, we would 
tentatively suggest that DLGNT-MC-1 tumors may best 
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Fig. 5  Clinical patient information of DLGNT-MC-1 (a) and 
DLGNT-MC-2 (b).Tumor location for 13 DLGNT-MC-1 and 12 
DLGNT-MC-2 (left panel) are shown. Numbers in circles repre-
sent the amount of patients displaying tumor occurrence in the spe-
cific region. Patients with multiple tumor sites are counted multiple 
times. Note: three cases (DLGNT-MC-1_16, DLGNT-MC-1_17 and 
DLGNT-MC-2_13) were contributed and previously reported by 
Chiang et  al. [9]. Due to preselection based on their exclusive spi-
nal involvement, these cases were excluded in the illustration. Age 
at diagnosis (middle panel) and gender distribution (right panel) are 
illustrated with numbers indicating group size
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correspond to WHO grade I and DLGNT-MC-2 to WHO 
II–III.
In summary, our study provides an additional layer to the 
current histopathological classification of DLGNT, which will 
be particularly important for the not insignificant fraction of 
patients where the histological and neuroimaging is not typical 
of the current description of this entity. Recurrent 1p deletion 
and MAPK/ERK pathway activation represent diagnostic and 
therapeutic biomarkers, respectively, and may become impor-
tant for the stratification into future clinical trials with, e.g., 
MEK or NTRK inhibitors, with the hope of ultimately improv-
ing the clinical outcome of patients with DLGNT.
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